AAV viral vector manufacturing yields remain too low for gene therapy scale-up, creating 12-24 month CDMO wait times and costs exceeding $1M per patient

Cell and gene therapy developers face a critical bottleneck in manufacturing adeno-associated virus (AAV) vectors at sufficient scale and purity, because AAV-based therapies require extremely high doses for therapeutic effect but current production processes yield far less vector per batch than needed. This forces companies into long CDMO (contract development and manufacturing organization) queues and results in per-patient treatment costs that strain any reimbursement model. Why it matters: gene therapies like Zolgensma ($2.1M per dose) and Casgevy depend on viral vector production that cannot scale efficiently, so CDMO capacity is severely constrained and wait times stretch to 12-24 months, so CDMOs maintain strong pricing power that inflates manufacturing costs, so gene therapy companies burn cash during manufacturing delays that threaten their survival (especially pre-revenue biotechs), so approved gene therapies remain inaccessible to most patients who need them due to supply limitations and extreme cost. The structural root cause is that AAV production relies on transient transfection of adherent HEK293 cells -- a process developed for research-scale work, not commercial manufacturing -- and the industry has not yet validated suspension-based or stable producer cell line platforms at GMP scale, while the small number of qualified CDMOs creates an oligopoly with limited incentive to reduce pricing.